Mesothelioma Medical

Some Elderly Patients may Not be Getting the Cancer Treatment They Need

January 31, 2018 | Throneberry Law Group

A recent study by the Winship Cancer Institute at Emory University reveals disparities in the treatment given to elderly lung cancer patients, including those fighting mesothelioma and other deadly cancers. The study shows why it is so important for all mesothelioma patients, regardless of their demographic, to educate themselves and be proactive in their cancer treatment to improve their prognosis and maximize their survival term.

According to the study, which surveyed over 12,000 lung cancer patients at least 80 years old, African American patients were 20% less likely to receive chemotherapy and radiation to treat their condition. Furthermore, the research revealed that patients that lacked a high school education were 15% less likely to receive the same treatment as those with more education.

Another interesting trait uncovered in the study is that men are 40% more likely to receive chemotherapy and radiation treatment than women. The survival benefit associated with combination therapy persisted even after accounting for factors like age, sex, race, income, and individual tumor characteristics.

The Difficulties Of Diagnosing Mesothelioma

December 21, 2017 | Throneberry Law Group

Mesothelioma is an aggressive and rare form of cancer that attacks tissues lining the lungs, heart or abdomen. Most people who have been diagnosed with mesothelioma have been exposed to asbestos at some point in their lives. Why is it so difficult to diagnose? Here are three major reasons that can help individuals and families understand why.

Rarity

Even though thousands of people are diagnosed each year, mesothelioma is still a rare form of cancer. Due to its rarity, many doctors are not familiar with the symptoms, which can lead to a misdiagnosis.

New Study Shows Improved Life Expectancy of Peritoneal Mesothelioma with Two-Stage Treatment

December 4, 2017 | Throneberry Law Group

A recent study published in the Annals of Surgical Oncology highlighted a promising treatment that could possibly extend the life expectancy for patients suffering from malignant peritoneal mesothelioma. According to the report, a large portion of patients in a studying undergoing two-stage cytoreduction and intraperitoneal chemotherapy regimen had a significantly longer lifespan thanks to the treatment.

The treatment worked by first putting the patient through cytoreductive surgery, a procedure that removes tumors from inside the abdominal wall of mesothelioma patients. After undergoing surgery, doctors treated the patients with intraperitoneal chemotherapy to help kill any mesothelioma tumors possible left over from the surgery.

Doctors then monitored patients with CT scans of the abdomen, chest, and pelvis every six months for signs of tumor growth. Patients with tumors received a second round of cytoreduction and intraperitoneal chemotherapy while those without tumors only received the chemotherapy portion of the treatment.